Rajesh A. Shenoi, PhD, is Senior Scientist and In-Charge, Centre for Drug Discovery of the Inter University Centre for Biomedical Research & Super Speciality Hospital. He was Scientist D (*Ad hoc*) at the Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram during 2015-2016 and Scientist/Engineer 'SC' at the Vikram Sarabhai Space Centre, ISRO, Thiruvananthapuram during 2004-2008. He was with the Centre for Blood Research and Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada during 2008-2014. He joined IUCBR & SSH on 2nd December 2016.

His multidisciplinary laboratory focuses on the design and synthesis of small organic molecules, controlled synthesis of polymers and nanoparticles, macromolecular drug design and development, biological evaluation and pathology-laboratory science. He has developed five patented technologies for clinical translation and interacted keenly with corporate liaison for patent filing and technology transfer. He has 17 peer-reviewed articles to his credit published in *Science Translational Medicine, Blood, Journal of the American Chemical Society, Biomaterials, ACS Nano, Nanomedicine: Nanotechnology, Biology & Medicine, Biomacromolecules and Journal of Biomedical Nanotechnology*, with a cumulative IF of 115 and *h*-index-9. He had moved to University of British Columbia after obtaining PhD from University of Pune, researching at CSIR-National Chemical Laboratory, Pune. He received his Masters degree in Chemistry from School of Chemical Sciences, Mahatma Gandhi University, Kottayam.

His research interests are: design and development of synthetic polymer-based heparin reversal agents, antithrombotic agents & polyphosphate inhibitors, novel pH sensitive dendritic biodegradable polymers for drug delivery & bioconjugation, macromolecular metal chelators & imaging agents, macromolecular drugs & prodrugs, polymeric biomaterials for immunomodulation & vaccine delivery and plant-based nanoformulations for inflammatory, infectious & neurodegenerative diseases. He is currently establishing a State-of-the-Art research facility for drug design and development, training and mentoring of undergraduate and postgraduate students and project planning for grants-in-aid.